Trial Profile
Trial of Perioperative Endocrine Therapy - Individualising Care
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Antineoplastics
- Indications Early breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms POETIC
- 01 Nov 2020 Results published in the Lancet Oncology.
- 19 Feb 2020 New source identified and integrated: (ClinicalTrials.gov: US National Institutes of Health: NCT02338310).
- 07 Aug 2019 Planned End Date changed from 31 Dec 2013 to 1 Aug 2028.